Transcatheter therapies for resistant hypertension: Clinical review

Table 1 Renal artery stenting/angioplasty in resistant hypertension

Ref.	Size	Follow up period	Mean SBP reduction with stenting/ angioplasty	Mean SBP reduction with medical therapy	P value
Cooper et al[3] (Coral trial)	947	43 mo	16.6 ± 21.2	15.6 ± 25.8	0.03
Van Jaarsveld et al[7] (DRASTIC trial)	106	12 mo	19	17	0.51
Plouin et al[5] (EMMA trial)	49	6 mo	12 ± 20	8 ± 16	0.46
Webster et al[6]	135	3-54 mo	34	8	0.018

SBP: Systolic blood pressure.

Table 2 Renal nerve denervation in resistant hypertension

Ref.	Sample size	Follow up duration	Mean SBP reduction in RDN group (in mmHg)	Mean SBP reduction in control group (in mmHg)	P value
Worthley et al[22] (EnilgHTN 1 trial)	46	6 mo	26	No randomized control group	0.0001
a Krum et al[28]	45	12 mo	27	No randomized control group	0.001
Simplicity HTN-1 investigatorsb	153	24 mo	32	No randomized control group	0.0001
Esler et al[12] (Simplicity HTN-2)	106	6 mo	32 ± 23	+ 1	0.0001
Bhatt et al[32] ( Symplicity HTN-3)	535	6 mo	14.13 ± 23.93	11.74 ± 25.94	< 0.001

^aFollow up data available for n = 9 at 12 mo;

^bFollow up data available for n = 18 at 24 mo. SBP: Systolic blood pressure; RDN: Renal denervation; HTN: Hypertension.